Andrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.
Andrei Gafita, MD, from the Department of Nuclear Medicine, Klinikum Rechts der Isar at Technical University Munich in Germany, discusses the overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who received 177Lutetium-prostate-specific membrane antigen (LuPSMA) radionuclide treatment.
Factors that showed shorter OS outcomes included a shorter time since diagnosis of prostate cancer and whether the patient had prior use of chemotherapy as treatment. Lower levels of hemoglobin, lower PSMA expression within tumor lesions a higher number of metastases, and higher levels of alkaline at baseline were also associated with shorter OS, according to Gafita.
Gafita says what this told investigators is that patients who are rapidly progressing after diagnosis are more likely to have a shorter OS, which makes sense with a more aggressive disease such as this.
This international multicenter retrospective analysis was presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program. The median OS was 13.0 months (95% CI, 11.6-14.4 months) at the median follow-up of 22.5 months. The median prostate-specific antigen progression-free survival was 4.0 months (95% CI, 3.2-4.7 months).